Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| GSK, Amicus begin second phase III study of Amigal for Fabry disease - pharmabiz.com |
 |
 |
|
pharmabiz.com The primary outcome of efficacy will be renal function as measured by Glomerular Filtration Rate (GFR). John F. Crowley, chairman and chief executive officer of Amicus, stated, “In collaboration with GSK we are pleased to announce the dosing of the |
